Mirum Pharmaceuticals, Inc.
MIRM
Classifica tra le azioni
#3274
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Prezzo delle azioni
$82.58
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$5.36B
Variazione (1 giorno)
3.05%
Variazione (1 anno)
13.08%
Paese
US
Scambia Mirum Pharmaceuticals, Inc. (MIRM)
Categoria
Healthcare
Rapporto P/B per Mirum Pharmaceuticals, Inc. (MIRM)
Rapporto P/B al October 2026 TTM: -486.22
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Mirum Pharmaceuticals, Inc., il rapporto P/B attuale (TTM) è -486.22. Alla fine del 2023, era pari a 4.85.
Storico del rapporto P/B per Mirum Pharmaceuticals, Inc. da 2018 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | -486.22 | -5,682.34% |
| 2024 | 8.71 | 79.44% |
| 2023 | 4.85 | -388.93% |
| 2022 | -1.68 | -141.75% |
| 2021 | 4.02 | -258.02% |
| 2020 | -2.55 | -68.43% |
| 2019 | -8.06 | -72.59% |
| 2018 | -29.42 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | -101.29% |
US
|
|
| 13.2547 | -102.73% |
US
|
|
| 4.208 | -100.87% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -101.27% |
NL
|
